

CLAIMS

1. A polypeptide that comprises at least four ISVDs, wherein each of said ISVDs comprises three complementarity determining regions (CDR1 to CDR3, respectively), wherein the at least four ISVDs are optionally linked via one or more peptidic linkers, and wherein:

- 5 a) a first ISVD specifically binds to IL-13 and comprises
- i. a CDR1 that is the amino acid sequence of SEQ ID NO: 7;
 - ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 12; and
 - iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 17;
- b) a second ISVD specifically binds to IL-13 and comprises
- 10 iv. a CDR1 that is the amino acid sequence of SEQ ID NO: 8;
- v. a CDR2 that is the amino acid sequence of SEQ ID NO: 13; and
 - vi. a CDR3 that is the amino acid sequence of SEQ ID NO: 18;
- c) a third ISVD specifically binds to TSLP and comprises
- vii. a CDR1 that is the amino acid sequence of SEQ ID NO: 9;
 - 15 viii. a CDR2 that is the amino acid sequence of SEQ ID NO: 14; and
 - ix. a CDR3 that is the amino acid sequence of SEQ ID NO: 19; and
- d) a fourth ISVD specifically binds to TSLP and comprises
- x. a CDR1 that is the amino acid sequence of SEQ ID NO: 11;
 - xi. a CDR2 that is the amino acid sequence of SEQ ID NO: 16; and
 - 20 xii. a CDR3 that is the amino acid sequence of SEQ ID NO: 21,

wherein the order of the ISVDs indicates their relative position to each other considered from the N-terminus to the C-terminus of said polypeptide.

2. The polypeptide according to claim 1, wherein:

- 25 a) the amino acid sequence of said first ISVD comprises a sequence identity of more than 90% with SEQ ID NO: 2;

b) the amino acid sequence of said second ISVD comprises a sequence identity of more than 90% with SEQ ID NO: 3;

c) the amino acid sequence of said third ISVD comprises a sequence identity of more than 90% identity with SEQ ID NO: 4; and

5 d) the amino acid sequence of said fourth ISVD comprises a sequence identity of more than 90% identity with SEQ ID NO: 6.

3. The polypeptide according to any of claims 1 and 2, wherein:

a) said first ISVD comprises the amino acid sequence of SEQ ID NO: 2;

10 b) said second ISVD comprises the amino acid sequence of SEQ ID NO: 3;

c) said third ISVD comprises the amino acid sequence of SEQ ID NO: 4; and

d) said fourth ISVD comprises the amino acid sequence of SEQ ID NO: 6.

15 4. The polypeptide according to any of claims 1 to 3, wherein said polypeptide further comprises one or more other groups, residues, moieties or binding units, optionally linked via one or more peptidic linkers, in which said one or more other groups, residues, moieties or binding units provide the polypeptide with increased half-life, compared to the corresponding polypeptide without said one or more other groups, residues, moieties or binding units.

20

5. The polypeptide according to claim 4, in which said one or more other groups, residues, moieties or binding units that provide the polypeptide with increased half-life is chosen from the group consisting of a polyethylene glycol molecule, serum proteins or fragments thereof, binding units that can bind to serum proteins, an Fc portion, and
25 small proteins or peptides that can bind to serum proteins.

6. The polypeptide according to any one of claims 4 and 5, in which said one or more other groups, residues, moieties or binding units that provide the polypeptide with increased

half-life is chosen from the group consisting of binding units that can bind to serum albumin (such as human serum albumin) or a serum immunoglobulin (such as IgG).

5 7. The polypeptide according to claim 6, in which said binding unit that provides the polypeptide with increased half-life is an ISVD that can bind to human serum albumin.

8. The polypeptide according to claim 7, wherein the ISVD binding to human serum albumin comprises

- 10 i. a CDR1 that is the amino acid sequence of SEQ ID NO: 10 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 10;
- ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 15 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 15; and
- 15 iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 20 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 20.

9. The polypeptide according to any of claims 7 and 8, wherein the ISVD binding to human serum albumin comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 10, a CDR2 that is the amino acid sequence of SEQ ID NO: 15 and a CDR3 that is the amino acid sequence of SEQ ID NO: 20.

20

10. The polypeptide according to any of claims 7 to 9, wherein the amino acid sequence of said ISVD binding to human serum albumin comprises a sequence identity of more than 90% with SEQ ID NO: 5; preferably wherein said ISVD binding to human serum albumin comprises the amino acid sequence of SEQ ID NO: 5.

25

11. The polypeptide according to any of claims 1 to 10, wherein the amino acid sequence of the polypeptide comprises a sequence identity of more than 90% with SEQ ID NO: 1.

12. The polypeptide according to any of claims 1 to 11, wherein the polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 1.

13. A nucleic acid comprising a nucleotide sequence that encodes a polypeptide according to any of claims 1 to 12.

14. A host or host cell comprising a nucleic acid according to claim 13.

15. A method for producing a polypeptide according to any of claims 1 to 12, said method at least comprising the steps of:

a) expressing, in a suitable host cell or host organism or in another suitable expression system, a nucleic acid according to claim 13; optionally followed by:

b) isolating and/or purifying the polypeptide according to any of claims 1 to 12.

16. A composition comprising at least one polypeptide according to any of claims 1 to 12, or a nucleic acid according to claim 13, optionally wherein the composition is a pharmaceutical composition which further comprises at least one pharmaceutically acceptable carrier, diluent or excipient and/or adjuvant, and optionally comprises one or more further pharmaceutically active polypeptides and/or compounds.

17. A polypeptide according to any of claims 1 to 12, or a composition according to claim 16, for use in treating an inflammatory disease, such as a type 2 inflammatory disease; preferably wherein the type 2 inflammatory disease is selected from asthma and atopic dermatitis.

18. The polypeptide according to any one of claims 1 to 12, wherein the at least four ISVDs are linked via one or more peptidic linkers.